Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL558256 | 0.77 | — | — | |
| SCHEMBL558255 | 0.77 | — | — | |
| SCHEMBL17654235 | 0.77 | SMPD3 (0.31) | ALDH1A1 | |
| SCHEMBL558539 | 0.76 | — | — | |
| SCHEMBL1526561 | 0.76 | — | — | |
| SCHEMBL1526240 | 0.76 | — | — | |
| SCHEMBL558540 | 0.76 | — | — | |
| SCHEMBL2265800 | 0.72 | — | — | |
| SCHEMBL2067812 | 0.72 | — | — | |
| SCHEMBL2265807 | 0.72 | KDM4E (0.37) | KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 328 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11851435-B2 | PTGR2 inhibitors and their use | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2023-12-26 | — | — | US | claimed |
| CN-111819176-B | 4-azaindole compounds | 百时美施贵宝公司 | 2023-12-15 | — | — | CN | claimed |
| US-20230279008-A1 | PTGR2 INHIBITORS AND THEIR USE | NATIONAL TAIWAN UNIVERSITY (TW) | 2023-09-07 | — | — | US | claimed |
| CN-113651760-A | Pyrimidine selenium benzoic acid derivative, preparation method thereof and application of pyrimidine selenium benzoic acid derivative as herbicide | 常州大学 | 2021-11-16 | — | — | CN | claimed |
| EP-2964630-B9 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2017-08-09 | — | — | EP | claimed |
| EP-2948151-B1 | AMMONIUM DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2017-05-31 | — | — | EP | claimed |
| US-9656992-B2 | Pyrimidine compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-23 | — | — | US | claimed |
| EP-2948445-B1 | GUANIDINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2017-05-17 | — | — | EP | claimed |
| EP-2964630-B1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2017-05-10 | — | — | EP | claimed |
| US-9624180-B2 | Squaric derivatives for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-04-18 | — | — | US | claimed |
| WO-2006113498-A2 | 2-AMINO-QUINAZ0LIN-5-ONES AS HSP90 INHIBITORS USEFUL IN TREATING PROLIFERATION DISEASES | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2006-10-26 | — | — | WO | claimed |
| US-20050113450-A1 | Antibacterial agents | PHARMACIA & UPJOHN COMPANY | 2005-05-26 | — | — | US | claimed |
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | claimed |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | claimed |
| US-20040058970-A1 | Cognition enhancing derivatives of isoxazole triazoloindane GABA-A alpha 5 receptor subunit ligands | MERCK SHARP & DOHME LTD. (GB) | 2004-03-25 | — | — | US | claimed |
| WO-2004018461-A2 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | claimed |
| WO-2004018428-A1 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | claimed |
| US-4048171-A | 1,4-Dihydropyridines | BAYER AKTIENGESELLSCHAFT (DT) | 1977-09-13 | — | — | US | claimed |
| US-4015000-A | 6-Acylamino-penam-3-carboxylic and 7-acylamino-3-cephem-4-carboxylic acids | CIBA-GEIGY CORPORATION (US) | 1977-03-29 | — | — | US | claimed |
| US-3950336-A | HYPOTENSIVE AGENTS, CORONARY VESSEL DILATORS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-04-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113450-A1 | Antibacterial agents | CLPP, SPOUT1, SAMHD1 | KMT2A 3645/4885ALDH1A1 462/4885 |
| US-11851435-B2 | PTGR2 inhibitors and their use | PTGFR, PTGIR, PTGDR2 | KMT2A 4016/4885ALDH1A1 1177/4885 |
| US-20040058970-A1 | Cognition enhancing derivatives of isoxazole triazoloindane GABA-A alpha 5 receptor subunit ligands | GABRA5, GABRA1, GABRB1 | KMT2A 3637/4885ALDH1A1 717/4885 |
| US-20230279008-A1 | PTGR2 INHIBITORS AND THEIR USE | PTGFR, PTGIR, PTGDR2 | KMT2A 4016/4885ALDH1A1 1177/4885 |
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | KMT2A 3181/4885ALDH1A1 123/4885 |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | KMT2A 2853/4885ALDH1A1 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.